Study wrapper · #176
Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.
Editor's note
A post hoc analysis pooling Eli Lilly's Phase 3 obesity programme (SURMOUNT-1 through -5, SURMOUNT-OSA and SUMMIT) to ask whether tirzepatide behaves differently in adults aged 65 and over. That question matters because older patients are underrepresented in registration trials, yet post hoc subgroup splits are exploratory: age was not a pre-specified randomisation factor, so this is hypothesis-consistent rather than confirmatory evidence. Researchers reported that weight reduction, cardiometabolic risk factors and quality-of-life measures in the older group broadly matched those in adults under 65, and that adverse-event rates versus placebo showed no clinically meaningful age-related excess for gastrointestinal tolerability, falls, fractures, depression, pancreatitis, or renal, hepatic, gallbladder and biliary events. Read against tirzepatide's large, high-quality Phase 3 base, this extends confidence to older adults but does not replace a trial designed to test them. Note too that trial participants are typically healthier than the general geriatric population, and the abstract does not detail muscle- or bone-loss outcomes that weight loss can raise in this age group.
Plain-language abstract
Tirzepatide is a once-weekly injected medicine, sold as Zepbound for weight management, that acts on two gut-hormone systems (GLP-1 and GIP). Most of its large trials did not focus on older people, so researchers went back and re-analysed data from Lilly's Phase 3 obesity trials to compare adults aged 65 and over against those under 65. This was an after-the-fact look at existing trial data rather than a new trial built to answer the question. They found that older adults lost a clinically meaningful amount of weight and saw improvements in heart- and metabolism-related risk factors and quality of life that were broadly similar to younger adults. When comparing side-effect rates against placebo, the older group showed no clearly greater risk of stomach and gut problems, falls, fractures, depression, pancreatitis, or kidney, liver, gallbladder and bile-duct problems, beyond what age itself brings. The authors conclude the benefit-and-risk picture in older adults looked comparable to younger adults, while noting the analysis supports, rather than proves, use in this group.